JP2023553216A5 - - Google Patents
Info
- Publication number
- JP2023553216A5 JP2023553216A5 JP2023559969A JP2023559969A JP2023553216A5 JP 2023553216 A5 JP2023553216 A5 JP 2023553216A5 JP 2023559969 A JP2023559969 A JP 2023559969A JP 2023559969 A JP2023559969 A JP 2023559969A JP 2023553216 A5 JP2023553216 A5 JP 2023553216A5
- Authority
- JP
- Japan
- Prior art keywords
- genetically modified
- polypeptide
- composition according
- amino acid
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063123281P | 2020-12-09 | 2020-12-09 | |
| US63/123,281 | 2020-12-09 | ||
| PCT/US2021/062484 WO2022125711A1 (en) | 2020-12-09 | 2021-12-08 | Targeted cytokine construct for engineered cell therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023553216A JP2023553216A (ja) | 2023-12-20 |
| JP2023553216A5 true JP2023553216A5 (cg-RX-API-DMAC7.html) | 2024-12-10 |
Family
ID=81972793
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023559969A Pending JP2023553216A (ja) | 2020-12-09 | 2021-12-08 | 遺伝子操作細胞療法のための標的化サイトカイン構築物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240043490A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4259213A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023553216A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230129983A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116829194A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021397271A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3201573A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022125711A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110325205B (zh) | 2016-12-22 | 2023-08-15 | 库尔生物制药有限公司 | T细胞调节性多聚体多肽及其使用方法 |
| US11851471B2 (en) | 2017-01-09 | 2023-12-26 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| KR20240005989A (ko) | 2017-03-15 | 2024-01-12 | 큐 바이오파마, 인크. | 면역 반응을 조절하는 방법 |
| WO2019139896A1 (en) | 2018-01-09 | 2019-07-18 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| IL296209A (en) | 2020-05-12 | 2022-11-01 | Cue Biopharma Inc | Multimeric t-cell modulatory polypeptides and methods of using them |
| KR20230010251A (ko) | 2020-05-13 | 2023-01-18 | 보넘 테라퓨틱스, 인크. | 단백질 복합체의 조성물 및 그의 사용 방법 |
| JP2023541366A (ja) | 2020-09-09 | 2023-10-02 | キュー バイオファーマ, インコーポレイテッド | 1型真性糖尿病(t1d)を治療するためのmhcクラスii t細胞調節多量体ポリペプチド及びその使用方法 |
| KR20230112632A (ko) | 2020-10-23 | 2023-07-27 | 애셔 바이오테라퓨틱스, 인크. | 면역 세포 기능을 조절하기 위한 cd8 항원 결합 분자와의 융합 |
| WO2022245500A1 (en) | 2021-05-19 | 2022-11-24 | Asher Biotherapeutics, Inc. | Il-21 polypeptides and targeted constructs |
| US20260022190A1 (en) * | 2022-07-08 | 2026-01-22 | Shenghe (China) Biopharmaceutical Co., Ltd. | Heterodimeric fusion protein and use thereof |
| CA3262929A1 (en) * | 2022-07-25 | 2024-02-01 | Sloan-Kettering Institute For Cancer Research | PREPARATION PROCESSES FOR ADOPTIVE CELL THERAPIES |
| CN121969385A (zh) * | 2023-09-11 | 2026-05-01 | 丹娜-法伯癌症研究院 | 含有il-2变体以增强car t细胞的功能性的car-衔接子 |
| CN117904196B (zh) * | 2024-01-05 | 2024-07-12 | 安徽大学 | 一种非小细胞肺癌组蛋白h1.4赖氨酸乙酰化点突变细胞模型的构建及其应用 |
| CN120943901A (zh) * | 2025-05-29 | 2025-11-14 | 北京肿瘤医院(北京大学肿瘤医院) | 经修饰的caix靶向环肽、核素标记物及其在肿瘤诊疗方面的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112016016658A2 (pt) * | 2014-02-06 | 2018-01-23 | F. Hoffmann-La Roche Ag | proteína de fusão de um anticorpo, polinucleotídeo, vetor, célula hospedeira, composição farmacêutica, métodos para produzir uma proteína de fusão e de tratamento de uma doença em um indivíduo e uso da proteína de fusão |
| US20200306301A1 (en) * | 2017-07-03 | 2020-10-01 | Torque Therapeutics, Inc. | Polynucleotides Encoding Immunostimulatory Fusion Molecules and Uses Thereof |
| CN118126157A (zh) * | 2017-08-03 | 2024-06-04 | 美国安进公司 | 白介素-21突变蛋白和治疗方法 |
| MX387358B (es) * | 2018-02-28 | 2025-03-18 | Pfizer | Variantes de il-15 y usos de las mismas |
| CN113924311A (zh) * | 2019-01-07 | 2022-01-11 | 印希比股份有限公司 | 包含修饰的il-2多肽的多肽及其用途 |
-
2021
- 2021-12-08 JP JP2023559969A patent/JP2023553216A/ja active Pending
- 2021-12-08 EP EP21904356.9A patent/EP4259213A4/en active Pending
- 2021-12-08 CA CA3201573A patent/CA3201573A1/en active Pending
- 2021-12-08 US US18/256,512 patent/US20240043490A1/en active Pending
- 2021-12-08 KR KR1020237022145A patent/KR20230129983A/ko active Pending
- 2021-12-08 CN CN202180093384.4A patent/CN116829194A/zh active Pending
- 2021-12-08 WO PCT/US2021/062484 patent/WO2022125711A1/en not_active Ceased
- 2021-12-08 AU AU2021397271A patent/AU2021397271A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2023233125B2 (en) | Anti-KRAS-G12D T cell receptors | |
| AU2018342245B2 (en) | Methods of isolating T cells having antigenic specificity for a p53 cancer-specific mutation | |
| Ghia et al. | Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22 | |
| TWI908730B (zh) | 識別p53中之r175h或y220c突變之t細胞受體 | |
| TWI713798B (zh) | 增加介白素-2(il-2)分泌量之方法和源自該方法之蛋白類 | |
| US10919950B2 (en) | Tumor-specific IFNA secretion by car T-cells to reprogram the solid tumor microenvironment | |
| JP2021502114A (ja) | 改変された免疫細胞およびその使用 | |
| Mrózek et al. | Role of interleukin-15 in the development of human CD56+ natural killer cells from CD34+ hematopoietic progenitor cells | |
| KR20120093002A (ko) | Nk 세포의 활성 측정을 이용한 암 진단 방법 및 진단 키트 | |
| JP2025163198A (ja) | キメラサイトカイン受容体 | |
| US20250129169A1 (en) | Surrogate cytokine polypeptides | |
| JP2022520777A (ja) | in vivoでの免疫細胞の増殖をブースト可能なアジュバント | |
| CN114901684A (zh) | 粒细胞集落刺激因子受体(g-csfr)的经修饰胞外结构域和结合其的细胞因子 | |
| TW201835100A (zh) | 新穎t細胞受體 | |
| WO2024213695A1 (en) | Method for producing the subunits of human interleukin 35 from interleukin 12 and interleukin 27 | |
| Liu et al. | Insights into human CD34+ hematopoietic stem/progenitor cells through a systematically proteomic survey coupled with transcriptome | |
| Chilakapati et al. | Structure-guided engineering of CCL27 enhances natural ligand CAR T-cells against CCR10 for multiple myeloma | |
| CN119371485B (zh) | 源自长链非编码rna slc12a5-as1的hla-a*11:01肾细胞癌肿瘤抗原短肽及其应用 | |
| CN119371486B (zh) | 源自长链非编码rna linc02717的hla-a*11:01肾细胞癌肿瘤抗原短肽 | |
| Di Roberto et al. | speedingCARs: accelerating the engineering of CAR T cells by signaling domain shuffling and single-cell sequencing | |
| CN119751558B (zh) | 源自长链非编码rna ensg00000286147的hla-a*24:02肾细胞癌肿瘤抗原短肽 | |
| WO2019122875A1 (en) | Chimeric antigen receptor | |
| CN119390792B (zh) | 源自人逆转录病毒herv3895基因的hla-a*2402肾细胞癌肿瘤抗原短肽 | |
| CN113785201B (zh) | 用于检测镍纹蛋白-β活性的方法 | |
| Bradl et al. | The pre‐B cell receptor and its ligands–it takes two to tango |